6-Aminoquinolones as New Potential Anti-HIV Agents
- 19 September 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (20) , 3799-3802
- https://doi.org/10.1021/jm9903390
Abstract
A series of 6-aminoquinolone compounds were evaluated for their in vitro activity against human immunodeficiency virus type 1 (HIV-1). Compound 12a, bearing a methyl substituent at the N-1 position and a 4-(2-pyridyl)-1-piperazine moiety at the C-7 position, was the most active in inhibiting HIV-1 replication on de novo infected C8166 human lymphoblastoid cell lines. The 12a EC50 value was 0.1 μM, a 7−20-fold lower concentration relative to that for compounds 8a and 7a containing a cyclopropyl and tert-butyl substituent at the N-1 position, respectively. When the C-6 amino group was replaced with a fluorine atom, a decreased antiviral effect was observed. The observed effects are selective, since potency is substantially reduced when testing the compounds against the herpes simplex virus type 1 (HSV-1). Active quinolone derivatives very efficiently interact with TAR RNA, which suggests a nucleic acid-targeted mechanism of action.Keywords
This publication has 5 references indexed in Scilit:
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivativesAntimicrobial Agents and Chemotherapy, 1997
- 6-Aminoquinolones: A New Class of Quinolone Antibacterials?Journal of Medicinal Chemistry, 1995
- Inhibition of HIV Infection by Caffeoylquinic Acid DerivativesAntiviral Chemistry and Chemotherapy, 1993
- Antibodies against metal chelatesNature, 1985